Rhythm Pharmaceuticals Inc. has announced new data from their clinical programs for acquired hypothalamic obesity, which were presented at the Endocrine Society's Annual Meeting (ENDO 2025) in San Francisco, CA. The presentations highlighted significant findings from the Phase 3 TRANSCEND trial, evaluating the efficacy of the MC4R agonists setmelanotide and bivamelagon. The data demonstrated clinically meaningful reductions in BMI for patients treated with these drugs. Specifically, setmelanotide showed a 19.8% placebo-adjusted difference in BMI reduction, with consistent results across various age and sex subgroups. Bivamelagon also showed promising results, with BMI reductions of up to 9.3% in specific dosage cohorts. These findings suggest potential therapeutic benefits for patients with acquired hypothalamic obesity. The full presentations from the ENDO 2025 conference are available on Rhythm Pharmaceuticals' website.